Affiliation:
1. Department of Breast and Thyroid Surgery, Affiliated Cancer Hospital of Xinjiang Medical University , Urumqi City, 830000 , Xinjiang , China
2. Department of Breast Cancer Surgery, Affiliated Tumor Hospital, Xinjiang Medical University , No. 789, Suzhou Road , Urumqi , Xinjiang, 830011 , China
Abstract
Abstract
The aim of this study was to investigate the frequency distribution of the cytochrome P450 (CYP450) enzymes, CYP2D6 and CYP2C19, and the form of tamoxifen metabolisation in premenopausal patients with breast cancer in the Han and Uygur ethnic groups of Xinjiang to guide rational clinical drug use. A total of 125 Han patients and 121 Uygur patients with premenopausal hormone-receptor-positive breast cancer treated at the Xinjiang Uygur Autonomous Region Cancer Hospital between 1 June 2011 and 1 December 2013 were selected. The common mutation sites in CYP450 were analysed using TaqMan® minor groove binder technology. Genetic testing was performed to determine other metabolic types of tamoxifen, and the genotypes and metabolic types were compared using a Chi-squared test. Between the Han and Uygur groups, there were significant differences in the frequencies of the CYP2D6 (*10/*10) and CYP2C19 (*1/*1) genotypes, with P-values of 0.002 and 0.015, respectively. Genotypes of CYP2D6 (*1/*1), CYP2D6 (*1/*5), CYP2D6 (*5/*5), CYP2D6 (*5/*10) and CYP2C19 (*3/*3) were expressed in the two patient groups, and the difference was not statistically significant (P > 0.05). In the Han patients, the proportions of extensive, intermediate and poor metabolisers of tamoxifen were 72, 24 and 4%, respectively, whereas those in the Uygur patients were 76.9, 17.4 and 5.7%, respectively, with no significant difference (P > 0.05). In conclusion, There were partial differences in the CYP2D6 and CYP2C19 gene polymorphisms of CYP450 between the Han and Uygur patients with premenopausal breast cancer, but there was no significant difference between the CYP2D6 and CYP2C19 phenotypes. Further research is needed to determine the relationship between the enzyme genetic differences of CYP450 and the pharmacokinetics and efficacy of tamoxifen. Although there were some differences in genotypes, these did not result in differences in the predicted tamoxifen metabolisation phenotype between the Han and Uygur patients with breast cancer. Therefore, the doses should be adjusted according to the individual genotype data.
Reference26 articles.
1. Brito LF, Kijas JW, Ventura RV. Genetic diversity and signatures of selection in various goat breeds revealed by genome-wide SNP markers. BMC Genomics. 2017;18:1–20.
2. Wang L, Wu Z, Zou C. Genetic diversity and signatures of selection in the mito-gynogenetic olive flounder Paralichthys olivaceus revealed by genome-wide SNP markers. Aquaculture. 2022;553:738062.
3. Niwa T, Yasuda S, Yamamoto Y, Murakami M, Ishii R. Contribution of the human cytochrome P450 2C subfamily to the metabolism of and the interactions with endogenous compounds including steroid hormones. Pharmazie. 2021 Dec;76(12):611–3.
4. Li H, Zhou L, Ma J, Zhu Y, Fan J, Li N, et al. Distribution and susceptibility of ERCC1/XPF gene polymorphisms in Han and Uygur women with breast cancer in Xinjiang, China. Cancer Med. 2020 Dec;9(24):9571–80.
5. He W, Eriksson M, Eliasson E, Grassmann F, Bäcklund M, Gabrielson M, et al. CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial. Ann Oncol. 2021 Oct;32(10):1286–93.